CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Toofan et al. showed that targeting CML CD34+ cells with Bone Morphogenetic Proteins (BMPs) receptor inhibitors in combination with TKIs interfered with cell cycle regulation, enhanced apoptosis, and reduced the number of CML CD34+ cells [28].